Current Report Filing (8-k)
July 02 2019 - 08:53AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
July 2, 2019
|
VARIAN
MEDICAL SYSTEMS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
1-7598
|
94-2359345
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
3100 Hansen Way, Palo Alto, CA
|
94304-1030
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(650) 493-4000
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
Trading Symbol(s)
|
Name of each exchange on which registered:
|
Common Stock, $1 par value
|
VAR
|
New York Stock Exchange
|
Item 8.01.
Other Events
.
Varian Medical Systems,
Inc. (the “
Company
”) announced on July 1, 2019 that it had entered into a definitive agreement to acquire certain
embolic bead assets from Boston Scientific Corporation for $90 million. The transaction is anticipated to close later in 2019 and
is subject to Federal Trade Commission, the closing of the proposed acquisition of BTG PLC by Boston Scientific Corporation and
other customary closing conditions. A copy of the press release is attached as
Exhibit 99.1
.
Item 9.01.
Financial Statements and Exhibits
.
|
(d)
|
Exhibits
.
|
|
|
|
|
|
The following exhibit is being furnished, and is not deemed to be filed:
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Varian Medical Systems, Inc.
|
|
|
|
|
By:
|
/s/ John W. Kuo
|
|
Name:
|
John W. Kuo
|
|
Title:
|
Senior Vice President, General Counsel and
|
|
|
Corporate Secretary
|
Dated: July 2, 2019
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Mar 2023 to Mar 2024